Business Wire
15 Aug 2026, 11:07 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Zymeworks Inc. is acquiring Theravance Biopharma, Inc. (NASDAQ: TBPH) for $17.00 per share. — M&A activity at a specific price typically creates a strong price floor and immediate valuation catalyst for the target company.
+0.80Law firm Halper Sadeh LLC is investigating whether Theravance and its board violated duties regarding the sale to Zymeworks. — Shareholder litigation investigations can create modest uncertainty and potential delays or adjustments to deal terms.
-0.20Which stocks this story touches
The company is the subject of a legal investigation regarding its sale to Zymeworks.
Continue reading
6 related stories
Search tags
Associated with a legal investigation regarding its acquisition of Theravance Biopharma.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
PRNewsWire
15h ago
